FiRa Consortium Unveils FiRa Core 3.0 Specifications and Certification Program

14.1.2025 14:00:00 CET | Business Wire | Press Release

The FiRa® Consortium announces the release of its Core 3.0 Specifications and Certification Program, notable milestones in ultra-wideband (UWB) technology development. These updates enhance UWB’s capabilities, enabling seamless interoperability and unlocking new possibilities for precise and secure ranging and positioning in diverse applications.

Features of the FiRa Core 3.0 Specifications and Certification Program

FiRa is introducing three major UWB features in its Core 3.0 Specifications. Advancements designed to enhance the efficiency and versatility of UWB systems include:

Hybrid UWB Scheduling (HUS): This feature – detailed in the FiRa MAC and FiRa UCI Technical Specifications – enables advanced UWB applications that require various combinations of FiRa features to work together deterministically, ensuring optimized performance in complex environments such as public transport systems.
Dedicated Data Transfer: Designed to use UWB for dedicated data transfer, this advancement allocates airtime exclusively for data transfer, independent of ranging operations. This is also detailed in the FiRa MAC, FiRa Link Layer, and FiRa UCI Technical Specifications.

The third enhancement adds the Car Connectivity Consortium® (CCC) Digital Key UWB feature to the Certification Program:

CCC Digital Key UWB: The CCC Digital Key UWB feature is used to measure the proximity of a mobile device to a car, employing a one-to-many double-sided two-way ranging protocol defined by the CCC. This enables drivers to unlock their car doors securely by deterring relay attacks.

FiRa Certification Program 3.0 – A Flexible Path to Interoperability

Building on these technical advancements, the Certification Program 3.0 allows devices to select specific features for certification. Devices certified under FiRa 3.0 can leverage these new capabilities, ensuring interoperability and enabling a broader scope of UWB-enabled applications.

The Certification Program 3.0 assures end users of the reliability and interoperability of FiRa-enabled devices, driving adoption and innovation across industries. Its rollout covering PHY, MAC, Link Layers, and Interoperability testing further solidifies UWB’s position within the IoT ecosystem.

“FiRa Core 3.0 represents an innovative step forward in advancing UWB technology,” said Clint Chaplin, FiRa Consortium Board Chair. “By addressing the need for simultaneous application support and improved data handling, these updates empower our members to innovate and meet the demands of increasingly nuanced use cases such as public transport fare collection, tap-free mobile payment, or logical access.”

FiRa Core 3.0 Specifications and Certification Program are available to FiRa Consortium members; nonmembers are able to purchase specifications. For more information about becoming a FiRa member, visit: https://www.firaconsortium.org/membership.

Learn more about what’s new with the Certification Program here.

About FiRa Consortium

The FiRa Consortium is a member-driven organization dedicated to transforming the way we interact with our environment by enabling precise location awareness for people and devices using the secured fine-ranging and positioning capabilities of Ultra-Wideband (UWB) technology. FiRa does this by driving the development of technical specifications and certification, advocating for effective regulations, and by defining a broad set of use cases for UWB. To learn more about UWB and the FiRa Consortium, visit www.firaconsortium.org.

©2025 FiRa Consortium. All rights reserved. FiRa, FiRa Consortium, the FiRa logo, the FiRa Certified logo, and the FiRa tagline are trademarks or registered trademarks of FiRa Consortium or its licensor(s)/ supplier(s) in the US and other countries and may not be used without permission. All other trademarks, service marks, and product or service names are trademarks or registered trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114593275/en/

Contacts

For more information, please contact:

Benjamin Guilloud
FiRa Consortium
Marketing Working Group Chairman
Telephone: +336 51 04 85 39
Email: press@firaconsortium.org

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom